Sedana Medical AB (publ) (SEDANA) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to today's Finwire broadcast presentation with Sedana Medical. After the presentation, there will be a question and answer session. So if you have any questions, you can submit them in English using the form on the right. With that said, I'll hand the floor to you. Please go ahead. Thank you for the introduction and a warm welcome to our Q1 report 2026. Sometimes the development of a company is shown best in quarters where you're facing some headwinds or adverse conditions. We have been through such a quarter in Q1 with significantly less patients and intensive care units in several of our main markets and also a nationwide strike that is affecting our operations in Spain. So for the first time since the year after COVID-19, we're seeing a slight sales decline. But despite all of these factors, we have delivered a positive EBITDA on the group level and double digit EBITDA even in our XUS business. And of course, I prefer quarters where things go a bit more in our favor or the market environment is at least neutral. But this Q1 really demonstrates that all the work we have done in transforming Sedana Medical into a fully customer focused company with a very lean backbone and cost structure is now really paying off. So let's jump right in on page three with the highlights of the quarter and the progress against our three priorities, sales growth, profitability and our US journey. Starting with sales. Last year we reached a new all time high with 200 million SEC net sales for the full year 2025. That was a good result, but also a very unusual pattern that we saw during the year with two very different halves of the year. In the first half, we sold for 107 million SEC, and in the second half, we sold for 93 million SEC. So the first half was 15% higher ...